美国食品药品监督管理局批准了针对晚期毛囊淋巴瘤的新快速方便治疗方法. FDA approves new fast, convenient treatment for advanced follicular lymphoma.

林业发展局批准了Genentech的Lunsumio VELO,用于治疗经过两次或两次以上治疗后复发或复发性脊髓炎淋巴瘤的成人。 The FDA has approved Genentech’s Lunsumio VELO for treating adults with relapsed or refractory follicular lymphoma after two or more prior therapies. 以一分钟内注射的亚皮注射取代了前一次耗时4小时的IV注入。 The subcutaneous injection, given in one minute, replaces a previous IV infusion that took up to four hours. 临床数据显示有75%的客观答复率和59%的完整答复率。 Clinical data showed a 75% objective response rate and 59% complete response rate. 新方法提供了更快的治疗,改善了病人的方便。 The new method offers faster treatment and improved patient convenience.